KRAS and cancer: It is notable that if the binding affinity of driver gene neoantigens (e.g., TP53 and KRAS) resulting hotspot mutations with MHC was improved, they could be used as therapeutic targets for a larger number of patients with a variety of cancer types, thus enabling more patients to receive immunotherapy.